Case Studies

/Resources/science-37-enables-real-time-data-collection-phase-4-study

Science 37 Delivers 96% Patient Retention in Fully Remote Study

Science 37 conducted a fully decentralized trial for patients with systemic lupus erythematosus and sjogren's syndrome using a single virtual site model. The sponsor aimed to enhance…

/Resources/science-37-delivers-96-patient-retention-fully-remote-study

Science 37 Delivers Diverse Patient Enrollment in Respiratory Clinical Trial

In a study for a respiratory syncytial virus (RSV) vaccine, Science 37 was contracted to deliver end-to-end remote clinical trial management and workflow orchestration. The biotech…

/Resources/science-37-delivers-diverse-enrollment-respiratory-clinical-trial

Science 37 Accelerates Enrollment for Dermatology Clinical Trial

Science 37 Accelerates Enrollment for Dermatology Trial

A biopharma company was conducting a Phase 2 randomized controlled trial in the United States for patients aged 18 and older with mild-to-moderate acne. The sponsor faced challenges…

/Resources/science-37-accelerates-enrollment-dermatology-trial

Science 37 Launches Infectious Disease Prevention Study in Just 12 Weeks

Virtual Site Launches Infectious Disease Prevention Study in Just 12 Weeks

A biotech sponsor contracted Science 37 to help enroll patients in a global Phase 2/3 registrational study with 95+ sites in 30 countries. Acting as a virtual site, Science 37 worked…

/Resources/virtual-site-launches-infectious-disease-prevention-study-just-12-weeks

Science 37 Accelerates Oncology Clinical Trial Timeline by 3 Years

Science 37 Delivers 3-Year Reduction in Oncology Clinical Trial Timeline

A biopharma company was investigating how its diagnostic screening technology—a one-time blood sample—performed against the gold-standard cancer screening procedure. The protocol…

/Resources/science-37-delivers-3-year-reduction-oncology-clinical-trial-timeline

Preliminary Results from an Interventional Decentralized Clinical Trial

A top pharma company partnered with Science 37 to conduct the first-ever interventional decentralized clinical trial (DCT) for patients with major depressive disorder (MDD). The trial…

/Resources/preliminary-results-interventional-decentralized-clinical-trial

The Metasite™ in Action: A Case Study Collection

The Science 37 Metasite™ is a virtual site that expands patient access to clinical trials and enables participation from anywhere. This booklet highlights real case studies,…

/Resources/metasitetm-action-case-study-collection

Breakthrough Decentralized Respiratory Trial with Pulmonary Function Testing

Science 37 Enables a Decentralized Model in Respiratory Trial with Pulmonary Function Testing

A large biopharma company was conducting a Phase IV trial of an approved biologic to understand its potential impact on sleep disturbance associated with asthma. Toward the end…

/Resources/science-37-metasite-action-science-37-enables-decentralized-model-respiratory-trial

The Science 37 Metasite in Action: A Fully Decentralized Trial for a Rare Vascular Disorder

A biopharma company was planning a Phase III, randomized, double-blind, placebo-controlled clinical trial for a drug to treat a rare and serious vascular disorder. Learn how the…

/Resources/science-37-metasite-action-fully-decentralized-trial-rare-vascular-disorder

The Science 37 Metasite in Action: How Science 37 Accelerated Enrollment for a Dermatology Trial

A biopharma company was conducting a Phase II randomized controlled clinical trial in the United States for a dermatological condition. The trial protocol required participation…

/Resources/science-37-metasite-action-how-science-37-accelerated-enrollment-dermatology-trial

Decentralized in Action: How Science 37 Accelerated Enrollment for a Diagnostic Oncology Trial

A biopharma company was investigating how its diagnostic screening technology—a one-time blood sample—performed against the gold standard cancer screening procedure. Download to learn…

/Resources/decentralized-action-how-science-37-accelerated-enrollment-diagnostic-oncology-trial

The Science 37 Metasite in Action: Accelerating Enrollment for an Infectious Disease Trial

A biopharma company was conducting a phase II randomized controlled trial for an infectious disease. The protocol required the participation of high-risk comorbidity patients ages 65+…

/Resources/science-37-metasite-action-accelerating-enrollment-infectious-disease-trial

Science 37 Accelerates Timelines and Expands Reach in Infectious Disease Study

A biotech company approached Science 37 to swiftly recruit, enroll, and treat a targeted population of participants across the United States. The study was unique due to the challenge…

/Resources/science-37-accelerates-timelines-and-expands-reach-infectious-disease-study-0

Science 37 Uses the Metasite to Support Clinical Trial in Rare Neurodegenerative Disease

An industry leading pharmaceutical company implemented the Science 37’s Metasite to reduce patient patient burden and accelerate trial timelines. Learn how the Metasite expanded reach…

/Resources/science-37-uses-metasite-support-clinical-trial-rare-neurodegenerative-disease

Science 37 Utilizes Flexibility of the Metasite Model in Study of Rare Disease

A biotech company approached Science 37 to develop a virtualized process to evaluate patients who may be eligible for an interventional study with a novel gene therapy …

/Resources/science-37-utilizes-flexibility-metasite-model-study-rare-disease

Science 37 Metasite Delivers Broad Patient Access in MDD Trial

A global leader in pharmaceuticals was looking to pilot an interventional study in major depressive disorder (MDD) using a Metasite model, in parallel to their Phase IIb trial.…

/Resources/science-37-metasite-delivers-broad-patient-access-mdd-trial

Evidence From Two Parallel Depression Trials

The adoption of the Decentralized Clinical Trial model in psychiatry has been tempered by concern regarding the conduct of clinician-reported outcomes conducted by centralized raters.…

MADRS_Scientific_poster_46x94_Web.pdf

/Resources/evidence-two-parallel-depression-trials

Science 37 Accelerates Timelines and Expands Reach in Infectious Disease Study

An industry-leading non profit institute was looking to execute a hybrid Phase II Randomized Controlled Study to determine the effectiveness of an interventional therapy. In this case…

/Resources/science-37-accelerates-timelines-and-expands-reach-infectious-disease-study

How Decentralized Clinical Trials Deliver on Diversity: A Case Study

Agile studies and fully Decentralized Clinical Trials are opening opportunities for any patient anywhere to benefit from participation in clinical research. This can have impacts on…

S37_ASCP_Poster_ChrisReist_3000x2000px (1).pdf

/Resources/how-decentralized-clinical-trials-deliver-diversity-case-study

Pioneering a First-Of-It’s-Kind Decentralized Clinical Trial in Depression

For this Phase II study of an oral investigative compound, Science 37® embarked on a journey to design the first ever decentralized clinical trial (DCT) in depression.

There is a significant unmet medical need for patients with Major Depressive Disorder (MDD) who either do not respond to, or do not tolerate, current augmentation approaches for…

Science 37 Poster Pres - CNS Summit 2021 - Chris Reist .pdf

/Resources/pioneering-first-its-kind-decentralized-clinical-trial-depression

Benefits of DCT technology, mobile nursing and connected devices on pediatric clinical trials

Combining Decentralized Clinical Trial Technology, Effective Mobile Nursing and Connected Devices To Deliver Pediatric Clinical Trials At Home

At DIA Europe 2022, Senior Director of Nursing Solutions for Science 37, Brianne Peters presented a poster on Combining DCT Technology, Effective Mobile Nursing and…

S37_Poster_DIA_Europe_R2 (1).pdf

/Resources/combining-dct-technology-effective-mobile-nursing-and-connected-devices-deliver-pediatric

Decentralized Model Delivers in Major Depressive Disorder Clinical Trial

A global leader in pharmaceuticals was looking to pilot the same interventional study in major depressive disorder (MDD) using a decentralized clinical trial (DCT) model to evaluate operational feasibility, data quality, enrollment speed, and retention. Science 37 helped expand reach beyond the confines of traditional sites, reaching patients who otherwise were unable to access the trial.

In parallel to their Phase IIb trial, a global leader in pharmaceuticals was looking to pilot the same interventional study in major depressive disorder (MDD) using a decentralized…

S37_CaseStudy_Metasite_Mar7c.pdf

/Resources/decentralized-model-delivers-major-depressive-disorder-clinical-trial

Enabling Diversity in Cancer Screening Study

We take a bespoke approach to all our trials. We understand every therapeutic area is different. We performed a careful review of trial design, inclusion/exclusion criteria, and review…

CASE-STUDY_Science-37_Diversity_Faster-Enrollment.pdf

/Resources/enabling-diversity-cancer-screening-study

Ensuring Diversity in a COVID-19 Study

We take a bespoke approach to all our trials. We understand every therapeutic area is different. We perform careful review of trial design, inclusion/exclusion criteria, and review of…